

Vitruvia Medical AG

Consolidated financial statement half-year as per June 30th, 2023.

All figures in EURO

Incl. Management report as per June 30th, 2023

Konsolidierte Bilanz per 30. Juni 2023

	<u>30.06.2023</u>	<u>31.12.2022</u>
	EURO	EURO
AKTIVEN		
Umlaufvermögen		
Flüssige Mittel	170'304	225'200
Forderungen aus Lieferungen und Leistungen	233'234	200'846
Sonstige Forderungen	110'793	94'283
Warenlager	78'287	88'514
Aktive Rechnungsabgrenzungen	3'203	8'593
	595'821	617'436
Anlagevermögen		
Mobile Sachanlagen	53'549	60'601
Immobilie Sachanlagen	2'504	2'504
Immaterielle Sachanlagen	25'000	25'000
Goodwill	1'026'123	1'231'348
	1'107'176	1'319'453
TOTAL AKTIVEN	1'702'997	1'936'889
PASSIVEN		
Kurzfristiges Fremdkapital		
Verbindlichkeiten aus Lieferungen und Leistungen	219'785	1'136'589
Kurzfristige Finanzverbindlichkeiten	189'731	201'387
Übrige kurzfristige Verbindlichkeiten	981'753	988'391
Passive Rechnungsabgrenzungen	97'013	139'879
	1'488'282	2'466'247
Langfristiges Fremdkapital		
Langfristige Finanzverbindlichkeiten	0	0
Wandelanleihe 6% 2022 - 2025, unter Rangrücktritt	1'068'354	1'068'354
	1'068'354	1'068'354
Eigenkapital		
Aktienkapital	2'310'559	1'692'043
Reserven aus Kapitaleinlagen	10'100'999	9'191'080
Verlustvortrag	-13'265'198	-12'480'835
	-853'639	-1'597'712
TOTAL PASSIVEN	1'702'997	1'936'889

Konsolidierte Erfolgsrechnung
1. Januar 2023 bis 30. Juni 2023
Vorjahr: 1. Januar 2022 bis 31. Dezember 2022

	<u>2023</u> EURO	<u>2022</u> EURO
ERTRAG		
Verkaufserlöse	840'246	1'418'449
Sonstige betriebliche Erlöse	15'271	107'080
Nettoerlöse aus Lieferungen und Leistungen	855'516	1'525'529
Materialaufwand / Dienstleistungsbezug	-191'673	-376'618
Bruttogewinn	663'843	1'148'910
Löhne und Gehälter	331'919	619'118
Sozialversicherungsbeiträge	67'434	124'605
Übriger Personalaufwand	0	0
Personalaufwand	399'352	743'724
Fremdmieten	31'126	86'391
Unterhalt, Reparaturen, Ersatz	50'769	26'554
Fahrzeugaufwand	22'383	30'279
Sachversicherungen	7'388	7'203
Büro - & Verwaltungsaufwand	85'124	1'106'122
PR & Werbung	28'948	54'981
Betrieblicher Nebenaufwand	0	5'742
Übriger betrieblicher Aufwand	225'739	1'317'273
Betriebliches Ergebnis vor Zinsen, Steuern und Abschreibungen (EBITA)	38'752	-912'086
Abschreibungen auf Sachanlagen	10'411	21'780
Abschreibungen Goodwill	205'225	410'449
Betriebliches Ergebnis vor Zinsen und Steuern (EBIT)	-176'884	-1'344'316
Finanzertrag	-79'364	-28'031
Ergebnis vor Steuern	-256'247	-1'372'347
ausserordentlicher Aufwand	0	94'690
Steuern	7'546	17'519
Ergebnis nach Steuern	-263'793	-1'484'556

Management Report

Vitruvia Medical AG achieves results as expected in the first half of 2023. The Board of Directors confirms the guidance for the full year.

Vitruvia Medical AG is on target in the first six months of 2023. The company generated consolidated revenues of approximately EUR 855,000.00 in the first half of 2023, with earnings before interest, taxes, depreciation and amortization of EUR -176,884.00.

Based on the results for the first half of 2023, which were as expected, the management confirms the outlook for the current full year. For this period, the Board of Directors expects consolidated revenues of approximately EUR 1.8 million. On a consolidated basis, Vitruvia Medical AG anticipates a further improvement in earnings compared to the previous year, which will, however, still be in negative territory.

Operational development in the first half of 2023

The cooperation between our subsidiary LT technologies GmbH & Co. KG with TRES MEDICO, Malaysia, which was entered into at the beginning of 2023, is developing very positively. As one of the few German companies in the repair service of surgical instruments, LT technologies can also offer its service "Made in Germany" internationally in Malaysia.

As a further milestone LT technologies was able to acquire the second largest full service company in the field of hospital management in Germany. LT technologies currently supports 4 large hospitals with repair services for surgical instruments.

The cooperation with a Swiss company, also in the repair service area, which was entered into at the end of last year, could be expanded on a monthly basis and will continue to grow.

There is now an online store for end users in German-speaking countries with small quantities of instrument repairs. LT technologies could secure it the exclusive contract at the repairs he instruments.

In general, the current social mood is contributing to an increased focus on sustainability, so that even in the medical sector instruments are increasingly being repaired and less replaced.

In addition to the encouraging development of the LT technologies investment, Vitruvia Medical AG continues to keep an eye out for interesting acquisition opportunities in order to expand its portfolio.

Anglikon, September 29, 2023

A handwritten signature in blue ink, appearing to read 'M. J. Janni', is positioned above the typed name.

Vitruvia Medical AG

Board of Directors